12 Michigan Drive
About Pillar Biosciences
Pillar Biosciences is a clinical cancer diagnostics company. We create precision next-generation sequencing (NGS) panels and software solutions to make clinical NGS robust, streamlined and cost-effective. Our SLIMamp™- and PiVAT™-based products are intended to deliver the most value to high-throughput reference labs and clinical oncology laboratories.
Founder & CEO: Gang Song PhD
Co-Founder & CSO: Zhaohui Wang PhD
Head of Corporate Development: Manfred Scholz PhD, MBA
Head of Product Management: Brian Dugan
Please click here for Pillar Biosciences' technology
6 articles with Pillar Biosciences
Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory
Pillar Biosciences today announced that its NGS laboratory, located in Natick, Massachusetts, has passed the onsite inspection and received Clinical Laboratory Improvement Amendment (CLIA) certification from the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS).
Pillar Biosciences to Collaborate with Labcorp on Precision Genomic Cancer Testing Using Next-Generation Sequencing
Pillar Biosciences today announced that it has entered into an agreement with Labcorp to provide genomic testing for people with cancer.
Pillar Biosciences today announced the appointment of Randy Pritchard as Chief Executive Officer.
Pillar Biosciences Receives Premarket Approval from FDA for its oncoReveal™ Dx Lung and Colon Cancer Assay
Pillar Biosciences Receives Premarket Approval from FDA for its oncoReveal ™ Dx Lung and Colon Cancer Assay
PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx cli
The SIPO of the People's Republic of China issued patent ZL201680001111.1 with a duration of 20 years.